Screened 2026-09-10 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Nutanix, Inc. holds its Accumulation at $65.42. The statistical read favours the sellers, held for 11 days.
As held on the ledger · 2026-09-10
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 11 days
Price at the screen
$65.42
Valuation
12.65 trailing · 24.60 forward price to earnings
Values screen
PASS
Beta
0.62
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.31%
Below 33%
Interest-bearing debt is just 12.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.91%
Below 33%
Cash held in interest-bearing accounts and securities is 14.9% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. The price runs 2.6% above the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +17% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Nutanix chases cloud growth without a moat
Picture a mid-sized firm swapping its old servers for a slick cloud setup. Nutanix sells the software that makes that switch feel simple. Yet the business shows little edge over bigger rivals, and the numbers do not scream opportunity.
Revenue is rising just 10 percent a year with profit margins stuck at 10 percent. The shares trade at 25 times forward earnings, only 6 percent below our fair value. A weak moat and middling growth leave little room for error at current prices.
Analysts still favour the name, but fierce competition can quickly cap pricing power and margins. Ethical checks clear, yet the financial profile does not.
Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NTNX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$67.64+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$67.64+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$67.64+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$67.64+12.5%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Markup$60.12+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-20Markup$60.12+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-19Markup$60.12+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-07Markup$60.12+12.1%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.1% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55.
2026-07-18Markup$53.64+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
